長時間作用型ドラッグデリバリー技術およびサービスの世界市場：技術別、剤形別、送達される分子タイプ別、使用材料別、流通チャネル別、地域別 - 分析と予測（2025年～2035年）

世界の長時間作用型ドラッグデリバリー技術およびサービスの市場規模は、長時間作用型ドラッグデリバリーソリューションの需要の高まりと採用の増加に牽引され、着実な成長を遂げています。

この拡大は、長時間作用型ドラッグデリバリーシステムが治療に非常に効果的なアプローチであるとの認識が高まっていることを反映しています。この成長の主な促進要因としては、慢性疾患の有病率の増加、長時間作用型ドラッグデリバリー技術の継続的な進歩、患者中心のヘルスケアモデルへの幅広いシフトなどが挙げられます。

革新的な製剤と長時間作用型ドラッグデリバリーシステムは市場の大きな牽引力となっており、製薬部門と技術部門の戦略的提携を促進し、投資を引き付けています。このような協力関係は、長時間作用型ドラッグデリバリーシステムの能力を向上させ、最終的に患者のコンプライアンスと転帰の改善につなげる上で極めて重要です。しかし、規制上のハードルやコストへの懸念といった課題は依然として残っているもの、長時間作用型ドラッグデリバリーにおける継続的な技術革新に支えられ、市場全体は力強い成長を示しています。

市場拡大の機会は特に新興地域で大きく、長時間作用型ドラッグデリバリーソリューションは高度な治療オプションに対する需要の高まりに対応できる態勢を整えています。新興経済諸国は、ヘルスケア投資の増加、インフラの改善、より効果的な慢性疾患管理へのニーズの高まりに後押しされ、この拡大において極めて重要な役割を果たすと予想されます。腫瘍、糖尿病、中枢神経障害などの治療分野における長時間作用型ドラッグデリバリーの応用拡大が市場開拓を加速させ、複数のヘルスケア部門にその裾野を広げています。

長時間作用型ドラッグデリバリー業界が進化を続ける中、バイオテクノロジーやナノテクノロジーの進歩を活用しながら、規制の複雑さ、コスト障壁、製剤の拡張性といった課題をうまく乗り切る企業は、長期的な成功に向けて有利な立場に立つことができると予測されます。イノベーションを促進し、戦略的パートナーシップを育成することで、これらの企業は長時間作用型ドラッグデリバリー市場の継続的な成熟に貢献し、より広範なアクセシビリティ、患者転帰の改善、持続可能な成長を確保することができます。

当レポートでは、世界の長時間作用型ドラッグデリバリー技術およびサービス市場について調査し、市場の概要とともに、技術別、剤形別、送達される分子タイプ別、使用材料別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

第1章 世界の長期作用型ドラッグデリバリー技術およびサービス市場概要

• 市場見通し
• 業界展望
• 市場力学

第2章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（技術別）、100万米ドル、2024年～2035年

• 長時間作用型注射剤
• 長時間作用型ハイドロゲル
• 長期作用型インプラント
• 長時間作用型マイクロニードル
• ナノクリスタル懸濁液

第3章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（剤形別）、100万米ドル、2024年～2035年

• 剤形のサマリー
• 長時間作用型注射剤
• 長期作用型埋め込み型
• 局所/経皮
• 膣
• その他

第4章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（送達される分子タイプ別）、100万米ドル、2024年～2035年

• 送達される分子タイプのサマリー
• 小分子
• 生物学的製剤
• その他

第5章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（使用材料別）、100万米ドル、2024年～2035年

• 使用材料のサマリー
• ポリマーベース
• 非ポリマーベース

第6章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（流通チャネル別）、100万米ドル、2024年～2035年

• 流通チャネルのサマリー
• 病院薬局
• 小売薬局

第7章 世界の長期作用型ドラッグデリバリー技術およびサービス市場分析（地域別）、100万米ドル、2024年～2035年

• 市場概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の長期作用型ドラッグデリバリー技術およびサービス市場-競合ベンチマーキングと企業プロファイル

• 競合ベンチマーキング
• 競合情勢
• 企業プロファイル
  • Adare Pharma Solution
  • Alkemeres
  • AMW GmbH
  • Creative Biolabs
  • Delpor, Inc.
  • Durect Corporation
  • Integral Biosystems
  • Nanexa AB
  • Corium, LLC
  • Hanmi Pharm Co. Ltd.
  • Camurus AB
  • Heron Therapeutics, Inc.

Global Long-Acting Drug Delivery Technologies and Services Market Overview

The global long-acting drug delivery technologies and services market is experiencing steady growth, driven by rising demand and increasing adoption of long-acting drug delivery solutions. This expansion reflects the growing recognition of long-acting drug delivery systems as a highly effective approach to treatment. Key drivers of this growth include the increasing prevalence of chronic diseases, continuous advancements in long-acting drug delivery technologies, and a broader shift toward patient-centric healthcare models.

Innovative formulations and long-acting drug delivery systems are gaining significant traction in the market, attracting both investments and fostering strategic collaborations between pharmaceutical and technology sectors. These collaborations are critical in advancing the capabilities of long-acting drug delivery systems, ultimately leading to improved patient compliance and outcomes. However, challenges such as regulatory hurdles and concerns over cost remain, yet the overall market trajectory suggests strong growth, supported by ongoing innovation in long-acting drug delivery.

Opportunities for market expansion are particularly strong in emerging regions, where long-acting drug delivery solutions are poised to meet the growing demand for advanced treatment options. Developing economies are expected to play a pivotal role in this expansion, fuelled by increasing healthcare investments, improving infrastructure, and the rising need for more effective chronic disease management. The growing application of long-acting drug delivery in therapeutic areas such as oncology, diabetes, and central nervous system disorders is accelerating market development and broadening its reach across multiple healthcare sectors.

As the long-acting drug delivery industry continues to evolve, companies that successfully navigate the challenges of regulatory complexities, cost barriers, and formulation scalability, while leveraging advancements in biotechnology and nanotechnology, will be well-positioned for long-term success. By fostering innovation and cultivating strategic partnerships, these companies can contribute to the continued maturation of the long-acting drug delivery market, ensuring broader accessibility, improved patient outcomes, and sustainable growth.

Industry Impact

The impact of long-acting drug delivery technologies and services on the pharmaceutical and healthcare industries is substantial, shaping various aspects of patient care and treatment strategies. A key benefit lies in improving patient adherence, as these systems typically require less frequent dosing, minimizing missed doses and enhancing overall treatment effectiveness. By promoting better adherence, long-acting drug delivery solutions contribute to improved patient outcomes, elevating the quality of healthcare while potentially lowering costs associated with untreated or inadequately managed conditions.

Moreover, the market has driven a surge of innovation and collaboration within the pharmaceutical industry. Companies are increasingly investing in research and development to formulate novel drug delivery systems, fostering a competitive environment that emphasizes efficiency and patient-focused solutions. The rise of interdisciplinary partnerships among pharmaceutical scientists, engineers, and clinicians is accelerating the advancement of groundbreaking technologies that surpass conventional drug delivery methods.

Market Segmentation:

Segmentation 1: by Technique

• Long-Acting Injectables
• Long-Acting Hydrogels
• Long-Acting Implants
• Long-Acting Microneedles
• Nanocrystal Suspensions

Long-Acting Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Technique)

In FY2024, the long-acting injectables segment led the global long-acting drug delivery technologies and services market (by technique). The growing preference for injectable formulations is driven by their ability to ensure sustained drug release over an extended period, providing benefits such as fewer dosing requirements and improved patient adherence. This dominance is especially notable in therapeutic areas where maintaining a consistent and prolonged therapeutic effect is essential, including chronic diseases and specific mental health disorders.

Segmentation 2: by Dosage Form

• Injectables
• Implantable
• Topical/Transdermal
• Vaginal
• Other Dosage Forms

Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Form)

In FY2024, the injectables segment led the global long-acting drug delivery technologies and services market (by dosage form). Known for their ability to provide sustained and controlled drug release through injection, injectables are gaining traction across multiple therapeutic areas, significantly shaping the evolution of long-acting drug delivery solutions.

Segmentation 3: by Type of Molecule Delivered

• Small Molecules
• Biologics
• Other Molecules

Small Molecules to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered)

In FY2024, the small molecules segment dominated the global long-acting drug delivery technologies and services market (by type of molecule delivered). Due to their molecular size and structure, small molecules are at the forefront of this market, driven by their versatility, broad therapeutic applications, and continuous advancements in drug formulation technologies.

Segmentation 4: by Material Used

• Polymer Based
• Non-Polymer Based

Polymer Based to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used)

In FY2024, the polymer-based segment led the global long-acting drug delivery technologies and services market by material used. This dominance highlights a strategic shift toward polymer utilization in developing long-acting drug delivery systems, driven by their versatility, biocompatibility, and effectiveness in modulating drug release profiles.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

The Asia-Pacific (APAC) region is experiencing substantial growth in the long-acting drug delivery technologies and services market, driven by rising demand, technological innovations, and an evolving healthcare landscape. This expansion is fuelled by a combination of factors that are accelerating the adoption and development of long-acting drug delivery solutions across various therapeutic applications.

Recent Developments in the Global Long-Acting Drug Delivery Technologies and Services Market

• In August 2023, AMW GmbH expanded into new European and international markets with the release of its first Notified Body Opinion (NBO) report for the goserelin implant.
• In November 2023, AMW GmbH and AdhexPharma announced a strategic collaboration to advance transdermal delivery systems.
• In February 2023, Innocore Pharmaceuticals, a Dutch company specializing in polymer-based long-acting injectables, secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch for simplified and effective vaccine administration.
• In March 2023, DelSiTech received approval to develop controlled and sustained-release injectables for a prophylactic HIV vaccine.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

• Growing adoption of sustained-release drugs and technologies: The growing adoption of sustained-release drugs and associated technologies is a major factor driving the expansion of the long-acting drug delivery technologies and services market. This trend signifies a shift toward the development of pharmaceutical solutions that provide extended therapeutic effects, minimizing the need for frequent dosing and enhancing patient adherence to treatment regimens.
• Advancements in long-acting drug delivery technologies

Market Restraints:

• Limitations of long-acting drug delivery technologies: The global long-acting drug delivery technologies and services market encounters challenges due to certain limitations inherent in these technologies, which can hinder their widespread adoption and growth. One significant drawback is the potential for a delayed onset of action, limiting their suitability for conditions that require immediate therapeutic effects.
• Regulatory challenges

Market Opportunities:

• Introduction of biologics and biosimilars compatibility in technologies: The ongoing development of long-acting drug delivery technologies compatible with biologics and biosimilars offers a promising opportunity for market expansion. These advancements have the potential to enhance treatment options across a wide range of therapeutic areas that depend on biologics and biosimilars, enabling more efficient, sustained drug release. By improving the stability, bioavailability, and patient adherence of these therapies, long-acting delivery systems can drive innovation in disease management and broaden the scope of biologic-based treatments.
• Advantages of long-acting drug delivery technologies

How can this report add value to an organization?

Workflow/Innovation Strategy: The long-acting drug delivery technologies and services market, categorized by technique, is segmented into various specialized methods, including long-acting injectables, long-acting hydrogels, long-acting implants, long-acting microneedles, and nanocrystal suspensions. Additionally, the study offers an in-depth analysis of the different types of molecules delivered and the materials used, providing a comprehensive understanding of the market landscape.

Growth/Marketing Strategy: The long-acting drug delivery technologies and services market includes a diverse range of products and solutions designed to prolong drug action. These technologies focus on enhancing patient adherence, minimizing dosing frequency, and optimizing therapeutic efficacy. The market encompasses various injectable drug delivery systems and services that enable sustained, controlled, or targeted drug release over an extended duration.

Competitive Strategy: The study analyses and profiles key players in the global long-acting drug delivery technologies and services market, including manufacturers engaged in new product launches, acquisitions, expansions, and strategic collaborations. Additionally, a detailed competitive benchmarking of market participants provides insights into their relative positioning, offering a clear view of the competitive landscape. Furthermore, an in-depth examination of strategic initiatives such as partnerships, agreements, and collaborations help identify untapped revenue opportunities within the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been calculated for FY2024 and projected for the period 2025-2035.
• The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2025 to 2035.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the long-acting drug delivery technologies and services market have been considered and profiled in the report.
• In the study, the primary respondent's verification has been considered to finalize the estimated market for the long-acting drug delivery technologies and services market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), and World Health Organization (WHO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculation

Key Market Players and Competition Synopsis

The long-acting drug delivery technologies and services competition aims to accelerate pharmaceutical innovation by promoting the creation of novel, efficient, and patient-centric drug delivery solutions. By encouraging the exploration and adoption of long-acting technologies, the competition addresses significant challenges associated with conventional drug administration, including frequent dosing schedules and low patient adherence.

Globally, the long-acting drug delivery technologies and services market is experiencing robust growth, propelled by the rising prevalence of chronic diseases and continuous advancements in drug formulation and delivery mechanisms. Emphasizing patient-centred care and personalized medicine, these innovative solutions enhance convenience and treatment efficacy, thereby improving patient compliance and overall therapeutic outcomes.

Some of the prominent companies in this market are:

• Adare Pharma Solutions
• Alkermes
• AMW GmbH
• Corium, LLC.
• Creative Biolabs
• Delpor, Inc.
• Durect Corporation
• Hanmi Pharm
• Heron Therapeutics, Inc.
• Integral BioSystems
• Nanexa AB

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Long-Acting Drug Delivery Technologies and Services Market Overview

• 1.1 Market Outlook
  • 1.1.1 Definitions
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Market Size, 2024 - 2035 (US$)
  • 1.1.4 Market Footprint and Growth Potential
• 1.2 Industry Outlook
  • 1.2.1 Introduction
  • 1.2.2 Market Overview and Ecosystem
  • 1.2.3 Key Benefits of Long-Acting Drug Delivery Technologies and Services in Industries
  • 1.2.4 Current and Future State of Long-Acting Drug Delivery Technologies and Services
• 1.3 Market Dynamics
  • 1.3.1 Market Opportunities and Trends
  • 1.3.2 Market Drivers
    • 1.3.2.1 Impact Analysis
  • 1.3.3 Market Restraints
    • 1.3.3.1 Impact Analysis

2. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Technology), $Million, 2024-2035

• 2.1 Long-Acting Injectables
• 2.2 Long-Acting Hydrogels
• 2.3 Long-Acting Implants
• 2.4 Long-Acting Microneedles
• 2.5 Nanocrystal Suspensions

3. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Dosage Form), $Million, 2024-2035

• 3.1 Dosage Form Summary
• 3.2 Long-Acting Injectables
• 3.3 Long-Acting Implantable
• 3.4 Topical/Transdermal
• 3.5 Vaginal
• 3.6 Others

4. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Type of Molecule Delivered), $Million, 2024-2035

• 4.1 Type of Molecule Delivered Summary
• 4.2 Small Molecules
• 4.3 Biologics
• 4.4 Other Molecules

5. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Material Used), $Million, 2024-2035

• 5.1 Material Used Summary
• 5.2 Polymer-based
• 5.3 Non-Polymer-based

6. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Distribution Channel), $Million, 2024-2035

• 6.1 Distribution Channel Summary
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies

7. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Region), $Million, 2024-2035

• 7.1 Market Overview
  • 7.1.1 North America
    • 7.1.1.1 U.S.
    • 7.1.1.2 Canada
  • 7.1.2 Europe
    • 7.1.2.1 U.K.
    • 7.1.2.2 Germany
    • 7.1.2.3 France
    • 7.1.2.4 Italy
    • 7.1.2.5 Spain
    • 7.1.2.6 Rest of Europe
  • 7.1.3 Asia Pacific
    • 7.1.3.1 Japan
    • 7.1.3.2 China
    • 7.1.3.3 India
    • 7.1.3.4 Australia
    • 7.1.3.5 Rest of Asia Pacific
  • 7.1.4 Latin America
  • 7.1.5 Middle East & Africa

8. Global Long-Acting Drug Delivery Technologies and Services Market - Competitive Benchmarking and Company Profiles

• 8.1 Competitive Benchmarking
• 8.2 Competitive Landscape
  • 8.2.1 Key Strategies and Developments by Company
    • 8.2.1.1 Funding Activities
    • 8.2.1.2 Mergers and Acquisitions
    • 8.2.1.3 Regulatory Approvals
    • 8.2.1.4 Partnerships, Collaborations, and Business Expansions
  • 8.2.2 Key Developments Analysis
  • 8.2.3 Company Share Analysis/ Company Position Analysis
• 8.3 Company Profiles
  • 8.3.1 Adare Pharma Solution
    • 8.3.1.1 Overview
    • 8.3.1.2 Top Products/Product Portfolio
    • 8.3.1.3 Key Personnel
    • 8.3.1.4 Top Competitors
    • 8.3.1.5 Analyst View
  • 8.3.2 Alkemeres
    • 8.3.2.1 Overview
    • 8.3.2.2 Top Products/Product Portfolio
    • 8.3.2.3 Key Personnel
    • 8.3.2.4 Top Competitors
    • 8.3.2.5 Analyst View
  • 8.3.3 AMW GmbH
    • 8.3.3.1 Overview
    • 8.3.3.2 Top Products/Product Portfolio
    • 8.3.3.3 Key Personnel
    • 8.3.3.4 Top Competitors
    • 8.3.3.5 Analyst View
  • 8.3.4 Creative Biolabs
    • 8.3.4.1 Overview
    • 8.3.4.2 Top Products/Product Portfolio
    • 8.3.4.3 Key Personnel
    • 8.3.4.4 Top Competitors
    • 8.3.4.5 Analyst View
  • 8.3.5 Delpor, Inc.
    • 8.3.5.1 Overview
    • 8.3.5.2 Top Products/Product Portfolio
    • 8.3.5.3 Key Personnel
    • 8.3.5.4 Top Competitors
    • 8.3.5.5 Analyst View
  • 8.3.6 Durect Corporation
    • 8.3.6.1 Overview
    • 8.3.6.2 Top Products/Product Portfolio
    • 8.3.6.3 Key Personnel
    • 8.3.6.4 Top Competitors
    • 8.3.6.5 Analyst View
  • 8.3.7 Integral Biosystems
    • 8.3.7.1 Overview
    • 8.3.7.2 Top Products/Product Portfolio
    • 8.3.7.3 Key Personnel
    • 8.3.7.4 Top Competitors
    • 8.3.7.5 Analyst View
  • 8.3.8 Nanexa AB
    • 8.3.8.1 Overview
    • 8.3.8.2 Top Products/Product Portfolio
    • 8.3.8.3 Key Personnel
    • 8.3.8.4 Top Competitors
    • 8.3.8.5 Analyst View
  • 8.3.9 Corium, LLC
    • 8.3.9.1 Overview
    • 8.3.9.2 Top Products/Product Portfolio
    • 8.3.9.3 Key Personnel
    • 8.3.9.4 Top Competitors
    • 8.3.9.5 Analyst View
  • 8.3.10 Hanmi Pharm Co. Ltd.
    • 8.3.10.1 Overview
    • 8.3.10.2 Top Products/Product Portfolio
    • 8.3.10.3 Key Personnel
    • 8.3.10.4 Top Competitors
    • 8.3.10.5 Analyst View
  • 8.3.11 Camurus AB
    • 8.3.11.1 Overview
    • 8.3.11.2 Top Products/Product Portfolio
    • 8.3.11.3 Key Personnel
    • 8.3.11.4 Top Competitors
    • 8.3.11.5 Analyst View
  • 8.3.12 Heron Therapeutics, Inc.
    • 8.3.12.1 Overview
    • 8.3.12.2 Top Products/Product Portfolio
    • 8.3.12.3 Key Personnel
    • 8.3.12.4 Top Competitors
    • 8.3.12.5 Analyst View